Circulating @entity28756 and microRNA-486 predict XXXX response: Moving towards precision health for diabetes prevention.

@entity1 @entity35212 @entity26261 @entity29087 @entity12585 @entity28756 @entity10019 @entity12721 @entity22077 @entity413
INTRODUCTION: The aims of this study were to compare microRNA (miR) expression between individuals with and without insulin resistance and to determine whether miRs predict response to @entity12585 treatment. MATERIALS AND METHODS: In a sample of 93 healthy adults, insulin resistance was defined as steady state plasma @entity413 (SSPG)>= 180mg/dL and insulin sensitive as <120mg/dL. Response to @entity12585 therapy was defined as >= 10% decrease in SSPG. We selected a panel of microRNAs based on prior evidence for a role in insulin or @entity413 metabolism. Fold change and Wilcoxon rank sum tests were calculated for the 25 miRs measured. RESULTS: At baseline, 81% (n=75) of @entity1 were insulin resistant. Five miRs were differentially expressed between the insulin resistant and sensitive groups: @entity35212 (1.45 fold change (FC)), @entity10019 (1.15 FC), @entity28756 (1.36 FC), @entity26261 (0.59 FC), and @entity22077 (1.21 FC) (all p<0.05). In the subset who were insulin resistant at baseline and received @entity12721 (n=47), 77% (n=36) showed improved insulin sensitivity. Six miRs were differentially expressed between responders compared to non-responders: miR-20b-5p (1.20 FC), @entity29087 , (0.92 FC), miR-214-3p (1.13 FC), @entity10019 (1.14 FC), @entity28756 (0.98 FC), and @entity22077 -5p (1.25 FC) (all p<0.05). DISCUSSION: This study is the first to report miRs associated with response to a pharmacologic intervention for insulin resistance. @entity28756 and @entity22077 -5p identified responders to @entity12585 therapy among the insulin resistant group.
